Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

1. What methods have been effective in promoting uptake of Pre-exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men

What methods have been effective in promoting uptake of Pre-exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men Knowledge & Library Services (KLS) Evidence Briefing What methods have been effective in promoting uptake of Pre- exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men (MSM), in developed cities comparable to London Nicola Pearce-Smith March 15 th 2019 What methods have been effective (...) in promoting uptake of PrEP among individuals at high risk of HIV KLS Evidence Briefing March 19th 2019 Research question This briefing summarises the evidence on the uptake of PrEP amongst high risk groups such as women, transgender, black Africans, sex workers, drug addicts and young people, from January 1 st 2017 to February 28 th 2019. Key messages • Barriers to PrEP uptake identified across all risk groups were safety, side effects, lack of knowledge, medication regimen, socioeconomic factors, stigma

2020 Publication 4890972

2. The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP

The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually (...) transmitted infection (STI) and considerations for their use of PrEP , , , , , , Questions What is the current evidence among women in high-income countries regarding HIV risk after acquiring a sexually transmitted infection (STI)? What does the evidence state regarding the use of pre-exposure prophylaxis (PrEP) to prevent HIV among women who have acquired an STI? Key take-home messages A recent study in the U.S. found that most women who were diagnosed with HIV did not have a reported STI in the past (1

2020 Ontario HIV Treatment Network

3. Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women

Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women (current immunosuppressants are listed in Table 2). Women with RA and IBD not on immunosuppressants and women with DM were considered at no increased risk compared with the general population. Screening recommendations based on these risks are summarizedinTable3. REFERENCES 1. GrulichAE,vanLeeuwenMT,FalsterMO,etal.Incidence ofcancersin peoplewithHIV/AIDScomparedwithimmunosuppressedtransplant recipients

2019 American Society for Clinical Pathology

4. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May (...) 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association , MD, MSc, FAHA, Chair , MD, Vice Chair , PhD , MD, MPH, FAHA , MD , MD, MSc , MD , MS , MD, FAHA , MD, MS Matthew J. Feinstein

2019 American Heart Association

5. HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing

HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing | The Ontario HIV Treatment Network The Ontario HIV Treatment Network HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues (...) related to linkage to care, interventions to increase HIV self-testing HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing , , , , , Questions What is the current evidence in high-income settings on HIV self-testing related to acceptability, potential benefits and harms, issues related to the linkage to care after a positive test, and interventions to increase HIV self-testing? Key take

2019 Ontario HIV Treatment Network

6. Doravirine for the treatment of HIV-1 in adults

Doravirine for the treatment of HIV-1 in adults Clinical Commissioning Policy: Doravirine for the treatment of HIV-1 in adults NHS England Reference: 190137P Standard Operating Procedure: Clinical Commissioning Policy: Doravirine for the treatment of HIV-1 in adults First published: November 2019 Prepared by National Institute for Health and Care Excellence (NICE) Commissioning Support Programme Published by NHS England, in electronic format only. Contents Policy Statement 4 Equality Statement (...) 4 Plain Language Summary 5 1 Introduction 7 2 Definitions 9 3 Aims and Objectives 10 4 Epidemiology and Needs Assessment 10 5 Evidence Base 10 6 Criteria for Commissioning 18 7 Patient Pathway 19 8 Governance Arrangements 19 9 Mechanism for Funding 19 10 Audit Requirements 19 11 Documents which have informed this Policy 20 12 Date of Review 20 References 21 Policy Statement NHS England will commission doravirine for the treatment of HIV-1 in adults, in accordance with the criteria outlined

2019 NHS England

7. Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection

Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection Prescrire IN ENGLISH - Spotlight ''Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection'', 1 November 2019 {1} {1} {1} | | > > > Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Dolutegravir (...) + rilpivirine (Juluca°) dual therapy in HIV infection FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options? Full review (3 pages) available for download by subscribers. Prescrire's rating NOTHING NEW In patients who have an undetectable viral load

2019 Prescrire

8. Unmet needs of Indigenous peoples living with HIV

Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV , , , , , , , , , Questions What are the unmet needs of Indigenous peoples living with HIV? What interventions, strategies, and programs have been used to address these needs? Key take-home messages In 2016, First Nations, Métis (...) , and Inuit peoples accounted for 4.9% of the Canadian population but represented 11.3% of all new HIV infections (1). When considering Indigenous health, conventional approaches to HIV and other communicable diseases are insufficient (2). Considerable disconnect exists between the priorities of the HIV care cascade and the experiences of Indigenous peoples living with HIV (3). The lack of coordination between mainstream HIV biomedical approaches and Indigenous worldviews appears to contribute to poor

2019 Ontario HIV Treatment Network

9. Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya

Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya Timely diagnosis of infant HIV infection is essential for antiretroviral therapy (ART) initiation. In a randomized controlled trial, we found the Texting Improves Testing (TextIT) intervention (a theory-based text messaging system) to be efficacious for improving infant HIV testing rates and maternal retention in prevention (...) of mother-to-child HIV transmission (PMTCT) programs. Using an implementation science approach, we aimed to evaluate real-world effectiveness of the intervention.In a pragmatic, cluster-randomized, stepped-wedge trial with 2 time periods of observation, we randomly allocated 10 clinics to begin implementing the intervention immediately and 10 clinics to begin implementing 6 months later. To approximate real-world conditions, inclusion criteria were broad. Women at clinics implementing the intervention

2019 EvidenceUpdates

10. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. (PubMed)

Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) infection who are receiving antiretroviral therapy are unknown.In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during

2019 NEJM

11. Dovato - dolutegravir / lamivudine - HIV-1 infection

Dovato - dolutegravir / lamivudine - HIV-1 infection dolutegravir / lamivudine | CADTH.ca Find the information you need dolutegravir / lamivudine dolutegravir / lamivudine Last Updated: October 3, 2019 Result type: Reports Project Number: SR0601-000 Product Line: Generic Name: dolutegravir / lamivudine Brand Name: Dovato Manufacturer: ViiV Healthcare Indications: HIV-1 infection Manufacturer Requested Reimbursement Criteria 1 : Indicated as a complete regimen for the treatment of Human (...) Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg. Submission Type: New Project Status: Active Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: September 30, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

12. Dolutegravir (Tivicay) - HIV-1 (Submission control number 207076)

Dolutegravir (Tivicay) - HIV-1 (Submission control number 207076) Available information for Tivicay - Submission control number 207076 - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Available information for Tivicay - Submission control number 207076 From Content and search results on this site are in the language provided by the manufacturer. Access and use of clinical information is governed by the . Submission information Submission control

2019 Health Canada - drugs and medical devices

13. Dolutegravir (Tivicay) - HIV-1 (Submission control number 192462)

Dolutegravir (Tivicay) - HIV-1 (Submission control number 192462) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

14. Ibalizumab (Trogarzo) - HIV-1

Ibalizumab (Trogarzo) - HIV-1 Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/502446/2019 EMEA/H/C/004961 Trogarzo (ibalizumab) An overview of Trogarzo and why it is authorised (...) in the EU What is Trogarzo and what is it used for? Trogarzo is a medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Trogarzo is given with other HIV medicines when none of the standard combinations work to control the infection because the virus is resistant to them (multi-drug resistant HIV). Trogarzo contains the active substance ibalizumab. How is Trogarzo used? The medicine can only be obtained

2019 European Medicines Agency - EPARs

15. Sexual and reproductive health and HIV: applying All Our Health

Sexual and reproductive health and HIV: applying All Our Health Sexual and reproductive health and HIV: applying All Our Health - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Sexual and reproductive health (...) and HIV: applying All Our Health Evidence and guidance on improving sexual health in communities with contraception, HIV and STI testing and easy access to advice. Published 1 April 2015 Last updated 17 September 2019 — From: Documents HTML Details Examples to inform healthcare professionals and maximise their contribution to health protection by improving sexual health outcomes. Published 1 April 2015 Last updated 17 September 2019 17 September 2019 Updated information on sexual and reproductive

2019 Public Health England

16. The risk of coercion in the context of HIV self-testing

The risk of coercion in the context of HIV self-testing The risk of coercion in the context of HIV self-testing | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The risk of coercion in the context of HIV self-testing The risk of coercion in the context of HIV self-testing , , , Questions What evidence is available on risk of coercion in the context of HIV self-testing? Key take-home messages While studies to date indicate that there are many benefits of HIV self-testing (...) (also known as home-testing) and the risk of harm through coerced self-testing is minimal, the risk of coercion still exists (1). HIV home testing in high-income settings is seen as less problematic because it is assumed that individuals would be able to pay for the test, do the test, and experience the testing process in a context free from coercion or abuse (2, 3). In high-income settings, HIV self-testing may be less challenging because existing systems ensure proper regulation, access to health

2019 Ontario HIV Treatment Network

17. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. (PubMed)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Accurate diagnosis of tuberculosis in people living with HIV is difficult. HIV-positive individuals have higher rates of extrapulmonary tuberculosis and the diagnosis of tuberculosis is often limited to imaging results. Ultrasound is such an imaging test that is widely used as a diagnostic tool (including point-of-care) in people suspected of having (...) abdominal tuberculosis or disseminated tuberculosis with abdominal involvement.To determine the diagnostic accuracy of abdominal ultrasound for detecting abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals.To investigate potential sources of heterogeneity in test accuracy, including clinical setting, ultrasound training level, and type of reference standard.We searched for publications in any language up to 4 April 2019 in the following databases

Full Text available with Trip Pro

2019 Cochrane

18. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. (PubMed)

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. The safety of CRISPR (clustered regularly interspaced short palindromic repeats)-based genome editing in the context of human gene therapy is largely unknown. CCR5 is a reasonable but not absolutely protective target for a cure of human immunodeficiency virus type 1 (HIV-1) infection, because CCR5-null blood cells are largely resistant to HIV-1 entry. We transplanted CRISPR-edited CCR5-ablated hematopoietic stem (...) and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia. The acute lymphoblastic leukemia was in complete remission with full donor chimerism, and donor cells carrying the ablated CCR5 persisted for more than 19 months without gene editing-related adverse events. The percentage of CD4+ cells with CCR5 ablation increased by a small degree during a period of antiretroviral-therapy interruption. Although we achieved successful transplantation and long-term engraftment

2019 NEJM

19. Dolutegravir lamivudine (Dovato) - human immunodeficiency virus type 1 (HIV-1)

Dolutegravir lamivudine (Dovato) - human immunodeficiency virus type 1 (HIV-1) Published 9 September 2019 1 Product update SMC2205 dolutegravir 50mg / lamivudine 300mg film-coated tablets (Dovato®) ViiV Healthcare Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated (...) submission dolutegravir / lamivudine (Dovato®) is accepted for use within NHSScotland. Indication under review: for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. In patients for whom this two-drug combination regimen is appropriate dolutegravir / lamivudine (Dovato®) offers a single tablet at no additional cost compared

2019 Scottish Medicines Consortium

20. Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study showed that telmisartan (80 mg/day) did not reduce insulin resistance in HIV-positive people taking antiretroviral drugs. {{author}} {{($index , , , , , , , , , & . Sudeep Pushpakom 1, † , Ruwanthi Kolamunnage-Dona 2, † , Claire Taylor 3 , Terry Foster 1 , Catherine Spowart 3 , Marta Garcia-Finana 2 , Graham J Kemp 4

2019 NIHR HTA programme